Gnomestar Craft Inc.
GNOM.CN
Canadian Securities Exchange0.01
CAD
- -
- -
Gnomestar Craft Inc.
GNOM.CN
(Canadian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Gnomestar Craft Inc. (GNOM.CN) produces and distributes craft cannabis products for medical and recreational use in Canada through its licensed indoor cultivation and processing facility in Delta, British Columbia. The company offers dried flower from proprietary cultivars such as Red Congolese and Comatose Kush; cannabis derivatives including oils, resins, extracts, hashes, waxes, tinctures, tonics, balms, and salves; food products containing cannabis such as chocolates, cookies, brownies, candy, and energy bars; as well as related items like fertilizers, plant nutrients, soil conditioners, and apparel including T-shirts, sweat tops, and hats. Incorporated in 2011 and formerly known as Vodis Pharmaceuticals Inc. until its rebranding to Gnomestar Craft Inc. in December 2020, the company operates a 12,000 square foot facility capable of yielding approximately 1,500 kg of craft cannabis annually at full capacity, targeting adult-use recreational and medical markets primarily within Canada. Headquartered at 8788 River Road, Delta, British Columbia, Gnomestar focuses on small-batch production emphasizing premium quality, hand-trimming, and avoidance of chemical pesticides through integrated pest management. Recent developments include a processing and sales agreement with BOAZ Pharmaceuticals Inc. dba BOAZ Craft Cannabis to distribute its products through BOAZ sales channels; partnerships with Shelter Craft Collective for supply chain services, brand development, and market access under its own Gnomestar brand or third-party labels; and management cease trade orders issued in 2022 due to late filing of annual financial statements, alongside CSE trading suspensions under regulatory policies. The company received Standard Cultivation and Processing licences under the Cannabis Act in January 2020 and continues R&D efforts on concentrates and extracts.